DelMar Pharmaceuticals, Inc. (DMPI) Expected to Announce Earnings of -$0.16 Per Share

Equities research analysts expect DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) to post ($0.16) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals posted earnings per share of ($0.13) in the same quarter last year, which would indicate a negative year over year growth rate of 23.1%. The business is scheduled to issue its next quarterly earnings report on Friday, February 9th.

On average, analysts expect that DelMar Pharmaceuticals will report full year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.65) to ($0.57). For the next financial year, analysts forecast that the company will post earnings of ($0.26) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for DelMar Pharmaceuticals.

DMPI has been the topic of a number of recent analyst reports. Maxim Group downgraded DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Dawson James reiterated a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Tuesday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of DelMar Pharmaceuticals in a research report on Thursday, October 5th.

WARNING: “DelMar Pharmaceuticals, Inc. (DMPI) Expected to Announce Earnings of -$0.16 Per Share” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at

Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) traded down $0.03 during mid-day trading on Friday, reaching $0.81. The company’s stock had a trading volume of 534,300 shares, compared to its average volume of 377,704. DelMar Pharmaceuticals has a 52 week low of $0.78 and a 52 week high of $5.39.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Sabby Management LLC bought a new stake in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned approximately 4.79% of DelMar Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 8.23% of the company’s stock.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply